CL2020002755A1 - Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. - Google Patents

Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.

Info

Publication number
CL2020002755A1
CL2020002755A1 CL2020002755A CL2020002755A CL2020002755A1 CL 2020002755 A1 CL2020002755 A1 CL 2020002755A1 CL 2020002755 A CL2020002755 A CL 2020002755A CL 2020002755 A CL2020002755 A CL 2020002755A CL 2020002755 A1 CL2020002755 A1 CL 2020002755A1
Authority
CL
Chile
Prior art keywords
nucleic acids
encode
recombinant nucleic
proteins
cosmetic proteins
Prior art date
Application number
CL2020002755A
Other languages
English (en)
Inventor
Suma Krishnan
Pooja Agarwal
Trevor Parry
Original Assignee
Krystal Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krystal Biotech Inc filed Critical Krystal Biotech Inc
Publication of CL2020002755A1 publication Critical patent/CL2020002755A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16631—Uses of virus other than therapeutic or vaccine, e.g. disinfectant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La presente descripción proporciona ácidos nucleicos recombinantes que comprenden uno o más polinucleótidos que codifican una o más proteínas cosméticas (por ejemplo, una o más proteínas de colágeno humanas); virus que comprenden los ácidos nucleicos recombinantes; composiciones (por ejemplo, formulaciones cosméticas) que comprenden los virus y/o ácidos nucleicos recombinantes; métodos para utilizarlos; y productos de elaboración o kits de estos.
CL2020002755A 2018-04-27 2020-10-23 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. CL2020002755A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862663476P 2018-04-27 2018-04-27

Publications (1)

Publication Number Publication Date
CL2020002755A1 true CL2020002755A1 (es) 2021-01-29

Family

ID=68291937

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2020002755A CL2020002755A1 (es) 2018-04-27 2020-10-23 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2023001338A CL2023001338A1 (es) 2018-04-27 2023-05-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000410A CL2024000410A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000411A CL2024000411A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000409A CL2024000409A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.

Family Applications After (4)

Application Number Title Priority Date Filing Date
CL2023001338A CL2023001338A1 (es) 2018-04-27 2023-05-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000410A CL2024000410A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000411A CL2024000411A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
CL2024000409A CL2024000409A1 (es) 2018-04-27 2024-02-09 Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.

Country Status (14)

Country Link
US (3) US10786438B2 (es)
EP (1) EP3810149A4 (es)
JP (4) JP7602999B2 (es)
KR (2) KR20260036286A (es)
CN (4) CN119499162A (es)
AU (3) AU2019260757B2 (es)
BR (1) BR112020021804A2 (es)
CA (1) CA3095187A1 (es)
CL (5) CL2020002755A1 (es)
CO (1) CO2020013588A2 (es)
MX (3) MX2020011257A (es)
SG (1) SG11202009895TA (es)
WO (1) WO2019210219A1 (es)
ZA (2) ZA202306237B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2796488T3 (es) 2016-04-08 2020-11-27 Krystal Biotech Inc Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
MX2020011257A (es) * 2018-04-27 2021-01-15 Krystal Biotech Inc Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
EP3856914A1 (en) 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
CN113454105A (zh) 2019-02-08 2021-09-28 克里斯托生物技术股份有限公司 用于递送cftr多肽的组合物和方法
EP4077688A1 (en) 2019-12-20 2022-10-26 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
CN113046331B (zh) * 2020-03-05 2022-09-13 北京唯源立康生物科技股份有限公司 非复制性重组疱疹病毒及其用途
CN111423516B (zh) * 2020-04-01 2022-02-11 广州佰斯伦医疗器械有限公司 一种蛋白及其在创口修复及抑菌中的应用
EP4262840A4 (en) * 2020-12-18 2024-11-20 Cullinan Amber Corp. IMMUNOMODULATORY MOLECULES LOCALIZED IN BI-FUNCTIONAL LINEAR FUSION COLLAGEN AND THEIR METHODS
CN112746076B (zh) * 2020-12-28 2023-05-12 中吉智药(南京)生物技术有限公司 一种密码子优化的col7a1基因及慢病毒和应用
IL307350A (en) 2021-04-02 2023-11-01 Krystal Biotech Inc Viral vectors for cancer treatment
CN114195884B (zh) * 2021-10-27 2024-03-29 禾美生物科技(浙江)有限公司 一种重组人源胶原蛋白及其制备方法
CN114656572B (zh) * 2022-02-25 2024-07-19 北京大学第一医院 一种bp180抗体快速检测试剂盒及其制备方法
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法
EP4374870A1 (en) * 2022-11-22 2024-05-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Codon-optimized oligonucleotide for induction of elastin de-novo synthesis in mammals
CN116218864B (zh) * 2023-04-10 2024-01-09 山东多美康生物医药有限公司 一种重组Ⅲ型人源化胶原蛋白α1及其表达载体和应用
EP4695408A1 (en) 2023-04-13 2026-02-18 Krystal Biotech, Inc. Methods and compositions for the treatment of conditions involving the eye
CN117230103B (zh) * 2023-09-25 2024-04-19 爱光生物医药(南昌)有限公司 17型人源化胶原蛋白及其蛋白支架、填充材料及应用
CN117402235B (zh) * 2023-10-25 2024-06-11 山西锦波生物医药股份有限公司 生物合成人体结构性材料iv型胶原蛋白的制备方法
CN120060268A (zh) * 2023-11-29 2025-05-30 深圳瑞吉生物科技有限公司 一种mRNA分子及其在制备美容护肤产品中的应用
CN117986353B (zh) * 2024-02-02 2024-08-30 西安巨子生物基因技术股份有限公司 重组人xvii型胶原蛋白、其制备方法及应用
KR102784640B1 (ko) * 2024-02-14 2025-03-26 대한켐텍 주식회사 피부 미용 개선용 펩타이드 및 이를 포함하는 원료 조성물
CN117866077B (zh) * 2024-03-13 2024-05-28 北京未名拾光生物技术有限公司 重组xvii型胶原蛋白及其表达体系
WO2025193129A1 (ru) * 2024-03-15 2025-09-18 Общество С Ограниченной Ответственностью "Валента-Интеллект" Средство для лечения буллезных генодерматозов
CN117986389B (zh) * 2024-04-02 2024-06-07 百肽德医药生物科技(广东)有限公司 一种重组人源化xvii型胶原蛋白、制备方法及应用
CN118324899B (zh) * 2024-06-13 2024-08-20 江苏亨瑞生物医药科技有限公司 一种重组xvii型人源化胶原蛋白、制备方法及其应用
CN121135861A (zh) * 2024-06-13 2025-12-16 南京诺唯赞生物科技股份有限公司 重组人源化胶原蛋白及其制备方法和用途
CN118530338B (zh) * 2024-06-17 2025-06-10 西安巨子生物基因技术股份有限公司 具有促毛囊生长作用的重组人xvii型胶原蛋白及其应用
CN118388666B (zh) * 2024-06-25 2024-09-20 山东美瑞生物技术有限公司 一种促进皮肤胶原蛋白和弹性蛋白再生的多肽及制备方法
CN118480554B (zh) * 2024-07-16 2024-10-18 苏州拾光医药生物科技有限公司 重组弹性蛋白及其表达体系和应用
WO2026046274A1 (zh) * 2024-08-29 2026-03-05 蕙景生物科技（上海）有限公司 改善皮肤状态的多核苷酸复合体
WO2026046285A1 (zh) * 2024-08-29 2026-03-05 仁景(苏州)生物科技有限公司 编码胶原蛋白的核酸分子及其用途
CN119264242A (zh) * 2024-10-11 2025-01-07 常州泰美瑞生物科技有限公司 一种重组xvii型胶原蛋白及其制备方法和应用
CN118949130B (zh) * 2024-10-18 2025-10-03 浙江清华长三角研究院 一种面部填充用胶原蛋白材料
WO2026094007A1 (en) 2024-11-01 2026-05-07 Krystal Biotech, Inc. Compositions and methods for the treatment of atpase disorders or diseases of the skin
CN119371518A (zh) * 2024-12-30 2025-01-28 冠图生物科技(潍坊)有限公司 一种高稳定重组人源化弹性蛋白、表达该蛋白的基因工程菌及其应用
CN119798414B (zh) * 2024-12-31 2026-05-08 西安巨子生物基因技术股份有限公司 重组人xxiii型胶原蛋白、其生产方法及用途
CN119591670B (zh) * 2025-01-20 2025-12-16 昆明理工大学 一种马乳源小分子肽及其应用
CN121627867A (zh) * 2025-11-20 2026-03-10 山西锦波生物医药股份有限公司 多肽、多肽构成的重组xi型人源化胶原蛋白及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
EP0704532B1 (en) * 1994-06-10 2002-09-11 United States Surgical Corporation Recombinant chimeric proteins and methods of use thereof
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
AU737727B2 (en) 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
EP1083951A4 (en) 1998-06-12 2004-07-07 Aradigm Corp METHOD FOR DISCHARGING POLYNUCLEOTIDS IN THE FORM OF AN AEROSOL IN THE RESPIRATION WAY
JP2003535565A (ja) 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
CN1285612C (zh) * 1999-11-12 2006-11-22 法布罗根股份有限公司 动物胶原和明胶
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
EP1356071B1 (en) 2000-11-28 2007-11-21 The University of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
TWI294461B (en) * 2004-12-28 2008-03-11 Ind Tech Res Inst Cell culture and method for screening for a compound useful in the treatment or prevention of hepatic cirrhosis
EP1838353A2 (en) 2005-01-21 2007-10-03 Introgen Therapeutics, Inc. Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
WO2007136428A2 (en) 2006-01-19 2007-11-29 Solazyme, Inc. Nutraceutical compositions from microalgae and related methods of production and administration
US20080119433A1 (en) 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
JP2008174459A (ja) * 2007-01-16 2008-07-31 Maruzen Pharmaceut Co Ltd 抗老化剤、並びに皮膚外用剤及び美容用飲食品
WO2008106646A2 (en) 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
US20100081707A1 (en) 2008-02-21 2010-04-01 Ali Robin R Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
US9938540B2 (en) 2008-11-12 2018-04-10 Ospedale San Raffaele S.R.L. Gene vector for inducing transgene-specific immune tolerance
EP3242136B1 (en) 2010-04-06 2021-05-19 Fertility Lab Sciences, LLC Secretome profile-facilitated in vitro fertilization
ES2590461T3 (es) 2010-07-02 2016-11-22 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii La transcriptasa inversa de la telomerasa como protección frente al envejecimiento
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
EP2766480B1 (en) 2011-10-11 2018-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Exon skipping therapy for dystrophic epidermolysis bullosa
SG10201604810UA (en) 2012-02-07 2016-08-30 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
GB201202561D0 (en) 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
WO2013151664A1 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
NZ701949A (en) 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
JP6726824B2 (ja) 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞
DK3184641T3 (da) 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
KR102415811B1 (ko) * 2014-01-31 2022-07-04 팩터 바이오사이언스 인크. 핵산 제조 및 송달을 위한 방법 및 산물
CN106456805B (zh) 2014-03-03 2020-01-10 阿尔伯特爱因斯坦医学院公司 重组单纯疱疹病毒2(hsv-2)疫苗载体
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
JP2015221759A (ja) * 2014-05-22 2015-12-10 株式会社東洋新薬 コラーゲン合成促進剤、ヒアルロン酸合成促進剤及びセラミド合成促進剤
FR3021541B1 (fr) 2014-05-28 2017-10-27 Oreal Procede cosmetique pour attenuer les rides
US20160082129A1 (en) 2014-09-24 2016-03-24 Aerpio Therapeutics, Inc. VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
MX387839B (es) 2014-10-31 2025-03-04 Senju Pharma Co Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
CN107405281A (zh) 2015-03-05 2017-11-28 雅芳产品公司 用于处理皮肤的方法
EP3302575A4 (en) 2015-05-28 2019-01-16 Coda Biotherapeutics GEMONEDITIERUNGSVEKTOREN
CN109069668B (zh) 2015-12-14 2023-04-18 宾夕法尼亚州大学信托人 用于眼病的基因疗法
ES2861453T3 (es) * 2016-01-04 2021-10-06 Univ Leland Stanford Junior Terapia génica para la epidermólisis ampollosa distrófica recesiva utilizando queratinocitos autólogos corregidos genéticamente
WO2017165806A1 (en) 2016-03-25 2017-09-28 Periphagen, Inc. Hsv vectors for delivery of nt3 and treatment of cipn
DK3432912T5 (da) 2016-03-25 2024-09-16 Periphagen Inc Hsv-vektorer med høj transduktion
ES2796488T3 (es) * 2016-04-08 2020-11-27 Krystal Biotech Inc Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
PT3475432T (pt) 2016-06-23 2022-08-02 Hopitaux Paris Assist Publique Vetores virais para tratamento de hiperatividade neurogénica do detrusor
EP3585896A1 (en) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of merosin-deficient cogenital muscular dystrophy (mdcmd) and other laminin, alpha 2 (lama2) gene related conditions or disorders
WO2018209358A2 (en) * 2017-05-12 2018-11-15 President And Fellows Of Harvard College Systemic delivery of polypeptides
EP3775236A1 (en) 2018-04-12 2021-02-17 Krystal Biotech, LLC Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
MX2020011257A (es) 2018-04-27 2021-01-15 Krystal Biotech Inc Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
WO2020006486A1 (en) 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
AU2019346549B2 (en) 2018-09-24 2024-09-12 Krystal Biotech, Inc. Compositions and methods for the treatment of Netherton Syndrome
EP3856914A1 (en) 2018-09-26 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases

Also Published As

Publication number Publication date
CN119523872A (zh) 2025-02-28
CO2020013588A2 (es) 2020-11-10
CL2024000411A1 (es) 2024-08-23
AU2026205071A1 (en) 2026-07-23
CA3095187A1 (en) 2019-10-31
AU2019260757B2 (en) 2023-09-28
JP7824338B2 (ja) 2026-03-04
JP2021521894A (ja) 2021-08-30
JP2026042028A (ja) 2026-03-10
AU2019260757A1 (en) 2020-12-03
KR20260036286A (ko) 2026-03-16
MX2025009002A (es) 2026-05-04
AU2023285844A1 (en) 2024-01-25
WO2019210219A1 (en) 2019-10-31
JP2024167302A (ja) 2024-12-03
EP3810149A1 (en) 2021-04-28
US20190328644A1 (en) 2019-10-31
SG11202009895TA (en) 2020-11-27
KR20210005141A (ko) 2021-01-13
CN112041434A (zh) 2020-12-04
NZ769822A (en) 2025-06-27
US10786438B2 (en) 2020-09-29
US20210045988A1 (en) 2021-02-18
BR112020021804A2 (pt) 2021-02-23
US12128122B2 (en) 2024-10-29
CL2023001338A1 (es) 2023-10-20
CN119499162A (zh) 2025-02-25
US20250255797A1 (en) 2025-08-14
JP7602999B2 (ja) 2024-12-19
MX2025009003A (es) 2026-05-04
ZA202306237B (en) 2024-11-27
CL2024000410A1 (es) 2024-08-23
MX2020011257A (es) 2021-01-15
JP2024056823A (ja) 2024-04-23
EP3810149A4 (en) 2022-08-24
AU2023285844B2 (en) 2026-04-02
ZA202501799B (en) 2025-06-25
CN119523873A (zh) 2025-02-28
CL2024000409A1 (es) 2024-08-23

Similar Documents

Publication Publication Date Title
CO2020013588A2 (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos
CO2020009402A2 (es) Proteínas de fusión fc il-22 y métodos de uso
NI201800121A (es) Proteínas de fusión gdf15 y usos de estas
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CO2018006301A2 (es) Mutantes de proteína f de rsv
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
MX2017010117A (es) Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
MX2016015235A (es) Nuevos polipeptidos de union especifica y usos de los mismos.
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
MX2017000169A (es) Un poliepitope quimerico de virus de dengue compuesto por fragmentos de proteinas no estructurales y su uso en una composicion inmunogenica contra infeccion de virus de dengue.
MX2019005102A (es) Poxvirus quimericos sinteticos.
EA202091769A1 (ru) Вакцины против вируса гриппа и пути их применения
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
CO2020013050A2 (es) Enzimas quinureninasa humanas y sus usos
BR112018073007A2 (pt) terapia de combinação inicial:reforço
MX2020010320A (es) Composiciones de erenumab y usos de las mismas.
MX2018005154A (es) Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana.
MX383505B (es) Eliminación de la cistina mediada por enzimas humanas.